Medical Discovery NewsBridging the World of Medical Discovery and You

Recent Episodes

AI and New Antibiotics


In medicine, AI has improved everything from surgery to medical research. Now, it may be delivering its best results yet: the development of new antibiotics.

Over time, bacteria have become resistant to treatment. The ones that can overcome multiple antibiotics are called "super bugs". Doctors have gotten better about not over-prescribing antibiotics. But that's less profitable for drug makers, which discourages them from developing new ones. That's why AI could be the answer.

Scientists used machine learning and AI to find new antibiotics against the deadly Acinetobacter baumannii. It's a major problem in hospitals and the military where it causes serious illnesses such as meningitis and pneumonia. Based on the bacterium's structural features, researchers gave the AI nearly seven thousand compounds to analyze. In just a few hours, the learning model picked out just over two hundred that could be new antibiotics. This hugely cut down time in the lab so that they only had to test two hundred forty compounds. Of those, nine could work and one called, abaucin, was a home run.

It was able to target and kill A. baumanni by interfering with lipoprotein trafficking which damages the membranes of the bacterium. Other experiments showed that abaucin prevented the bacterium from establishing wound infections in mice. This work shows us that AI can help us find not only antibiotics but other effective drugs. It could have huge payoffs for our health.

You can now hear additional episodes on many of your favorite podcast providers - visit Buzzsprout to subscribe.

More Information

AI Could Quickly Screen Thousands of Antibiotics to Tackle Superbugs
As the threat of antibiotic resistance increases, new antibiotics are imperative-and AI could widen the pipeline...

Using AI, scientists find a drug that could combat drug-resistant infections
The machine-learning algorithm identified a compound that kills Acinetobacter baumannii, a bacterium that lurks in many hospital settings...

Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii
Acinetobacter baumannii is a nosocomial Gram-negative pathogen that often displays multidrug resistance. Discovering new antibiotics against A. baumannii has proven challenging through conventional screening approaches. Fortunately, machine learning methods allow for the rapid exploration of chemical space, increasing the probability of discovering new antibacterial molecules...


Medicine is constantly advancing – that is a great thing about life in the 21st century. But it doesn’t just happen. Dedicated biomedical scientists are making discoveries that translate into those new medical advances.

Biomedical science is broad, encompassing everything from social science to microbiology, biochemistry, epidemiology, to structural biology and bioinformatics to name just a few areas. And, it can involve basic fundamental biology, the use of AI and chemistry to clinical studies that evaluate new medicines in patients.

No matter the research focus, the goal is always the same, to advance human health. It may take a few months, a few years or for fundamental science, a few decades. Few people make the connection that biomedical science is medicine and that biomedical scientists are working today on the medicine of tomorrow. Our weekly 500-word newspaper columns and 2-minute radio shows and podcasts provide insights into a broad range of biomedical science topics.

Medical Discovery News is dedicated to explaining discoveries in biomedical research and their promise for the future of medicine.


Alternatively, you can copy and paste the following web address (URL) into iTunes as a new subscription:

You can also search and subscribe to "Medical Discovery News" in the podcast section of iTunes.

See all podcasts and radio stations

The web site and Medical Discovery News radio program (Program) are made possible by The University of Texas Medical Branch at Galveston (UTMB)as a community service and are intended to advance UTMB's mission of providing scholarly teaching, innovative scientific investigation, and state-of-the-art patient care in a learning environment to better the health of society and its commitment to the discovery of new innovative biomedical and health services knowledge leading to increasingly effective and accessible health care for the citizens of Texas.

All information provided on the web site and in the Program is for informational purposes only and is not intended for use as diagnosis or treatment of a health problem or as a substitute for consulting a licensed medical professional. Any information obtained by participating as a web site visitor or program listener is not intended to and should not be considered to constitute medical advice.

Thoughts and opinions expressed on the Program or on the website are those of the authors or guests and do not necessarily reflect the opinions of UTMB. The provision of links to other websites is not to be construed as written or implied sponsorship or endorsement of such websites by UTMB.

Please contact Dr. David Niesel or Dr. Norbert Herzog via email with any concerns, suggestions or comments.

All rights are reserved to information provided on the website or other information sources. No part of these programs can be reproduced stored in a retrieval system or transcribed in any form or by any means for personal or financial gained without the express written permission of Drs. Niesel and Dr. Herzog.